Relapsed/Refractory Marginal Zone Lymphoma
1 clinical trials · Condition
◉ Watch Relapsed/Refractory Marginal Zone Lymphoma
| Record | Firm | Date |
|---|---|---|
| Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma (NCT06082102) | Beijing InnoCare Pharma Tech Co., Ltd. | 2023-12-19 |
Track Relapsed/Refractory Marginal Zone Lymphoma automatically
Every clearance here is in the API, with alerts when new ones post.